Berlin-based naturalX Health Ventures has announced a €100 million fund focused exclusively on consumer health startups in Europe. The fund, which marks the first of its kind in the European market, aims to support the transformation from reactive healthcare to proactive health management.
Led by German entrepreneur Marvin Amberg in cooperation with Schwabe Group, a global leader in plant-based pharmaceuticals, naturalX will primarily target Series-A investments with initial investments ranging from €3-5 million, and up to €10 million available per company. The fund maintains flexibility to participate in late Seed and Series-B rounds and can act as either lead or co-investor.
“I am very excited to double down on our thesis with the official launch of naturalX. The consumer health space has been overlooked by investors. We see an inflection point in Europe now, as consumers are finally taking more charge of their own health. Startups in the space need a partner with a shared vision,” said Marvin Amberg, founder of naturalX Health Ventures.
During its 18-month ramp-up phase, the fund has already invested in several companies, including mybacs, Flow Neuroscience, Kyan Health, and Meela. The fund’s launch comes as consumer attitudes toward healthcare continue to evolve, accelerated by the COVID-19 pandemic and rising health literacy driven by influential voices in the space.
The investment strategy focuses on proactive health solutions across various areas including sleep, gut health, prevention, and longevity, with special emphasis on mental health. This approach combines Schwabe Group’s pharmaceutical expertise with modern digital health innovation.
“We analysed the U.S. health market and in many successful startups, the consumer is already at the centre. Our thesis is that this is just the beginning, and the European market will develop in a similar pattern. While we start to see some examples of consumer-focused healthcare companies in Europe reaching meaningful scale and significant funding, such as Oura or Neko Health, we think this market deserves more attention,” Amberg added.
Portfolio companies have already reported positive experiences with the fund. Carl-Philipp von Polheim, Founder of mybacs, a DTC probiotic subscription startup, noted: “naturalX led our Series-A round and has been an exceptional partner, bringing not only capital but also invaluable knowledge of the nutritional supplement and broader consumer health market. Their pragmatic, fast decision-making allows us to focus on growing our business.”
Vlad Gheorghiu, Founder of mental health platform Kyan Health, shared similar sentiments: “At Kyan Health, we are dedicated to proactive mental health management—empowering individuals before issues escalate. naturalX shares this vision, recognizing that prevention is key to lasting impact. Their deep expertise and strategic approach make them an ideal partner in driving meaningful change for millions.”
